Abstract
Colchicine is a unique anti-inflammatory drug with respect to its limited clinical usefulness and its mode of action. Colchicine is mainly indicated for the treatment and prophylaxis of gout and familial Mediterranean fever. Its mode of action includes modulation of chemokine and prostanoid production and inhibition of neutrophil and endothelial cell adhesion molecules by which it interferes with the initiation and amplification of the joint inflammation. This paper discusses its adverse effects and indications.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References and Recommended Reading
Hartung EF: History of the use of colchicum and related medicaments in gout. Ann Rheum Dis 1954, 13:190–200.
Pelletier PJ, Caventou JB: Examen clinique de plusiers vegetaux de la famille des colchicees et du principe actif qu’ils enferment. Ann Chim Phys 1820, 14:69.
Wallace SL, Omokoku B, Ertel NH: Colchicine plasma levels: implications as to pharmacology and mechanism of action. Am J Med 1970, 48:443–448.
Wallace SL, Ertel NH: Plasma levels of colchicine after oral administration of a single dose. Metabolism 1973, 22:749–753.
Rochdi M, Sabouraud A, Girre C, et al.: Pharmacokinetics and absolute bioavailability of colchicine after i.v. and oral administration in healthy human volunteers and elderly subjects. Eur J Clin Pharmacol 1994, 46:351–354.
Sabouraud A, Chappey O, Dupin T, Scherrmann JM: Binding of colchicine and thiocolchicoside to human serum proteins and blood cells. Int J Clin Pharmacol Ther 1994, 32:429–432.
Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM: Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. J Clin Pharmacol 1996, 36:874–883.
Chappey ON, Niel E, Wautier JL, et al.: Colchicine deposition in human leukocytes after single and multiple oral administration. Clin Pharmacol Ther 1993, 54:360–367.
Ben-Chetrit E, Scherrmann JM, Zylber-Katz E, Levy M: Colchicine disposition in patients with familial Mediterranean fever with renal impairment. J Rheumatol 1994, 21:710–713.
Wallace SL: Colchicine: clinical pharmacology in acute gouty arthritis. Am J Med 1961, 30:439.
Malawista SE, Bensch KG: Human polymorphonuclear leukocytes: demonstration of microtubules and effect of colchicine. Science 1967, 156:521–522.
Malawista SE: Colchicine: a common mechanism for its antiinflammatory and anti-mitotic effects. Arthritis Rheum 1968, 11:191–197.
Bessis M, Breton-Gorius J: Rapports entre noyau et centrioles dans les granulocytes étalalés. Rule des microtubules. Nouvelle Revue Francaise d’Hématologie 1967, 7:601–620.
Sackett DL, Varma JK: Molecular mechanism of colchicine action: induced local unfolding of b-tubulin. Biochemistry 1993, 32:13560–13565.
Van de Candelaere A, Martin SR, Engelborghs Y: Response of microtubules to the addition of colchicine and tubulincolchicine: evaluation of models for the interaction of drugs with microtubules. Biochem J 1997, 323:189–196.
Malawista SE: The action of colchicine in acute gouty arthritis. Arthritis Rheum 1975, 18:835–846.
Landis CL, Haskard DO: Pathogenesis of crystal-induced inflammation. Curr Rheumatol Rep 2001, 3:36–41. This paper summarizes the latest studies on the importance of various inflammatory cells and cytokines in the initiation, amplification, and spontaneous cessation of gout attack.
Di Giovine FS, Malawista SE, Thornton E, Duff GW: Urate crystals stimulate production of tumor necrosis factor alfa from human blood monocytes and synovial cells: cytokine mRNA and protein kinetics, and cellular ditribution. J Clin Invest 1991, 87:1375–1381.
Roberge CJ, Grassi J, de Medicis R, et al.: Crystal-neutrophil interactions lead to interleukin-1 synthesis. Agents Actions 1991, 34:38–41.
Li Z, Davis GS, Mohr C, et al.: Inhibition of LPS-induced tumor necrosis factor-a production by colchicine and other microtubules disrupting drugs. Immunobiology 1996, 195:624–639.
Ding AH, Porteu F, Sanchez E, Nathan CF: Downregulation of tumor necrosis factor receptors on macrophages and endothelial cells by mictotubule depolarizing agents. J Exp Med 1990, 171:715–727.
Serhen CN, Lundberg U, Weissmann G, Samuelsson B: Formation of leukotrienes and hydroxy acids from human neutrophils and platelets exposed to monosodium urate. Prostaglandins 1984, 27:503–581.
Reibman J, Haines KA, Rich AM, et al.: Colchicine inhibits ionophor-induced formation of leukotriene B4 by human neutrophils: the role of microtubules. J Immunol 1986, 136:1027–1032.
Ehrenfeld M, Levy M, Bar Eli M, et al.: Effect of colchicine on polymorphonuclear leukocyte chemotaxis in human volunteers. Br J Clin Pharmacol 1980, 10:297–300.
Hambleton P, Miller P: Pharmacological investigation of acute cellular accumulation in immunological air pouch inflammation. Agents Actions 1989, 28:73–77.
Liu RU, O’Connell M, Johnson K, et al.: Extracellular signalregulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor _B transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum 2000, 43:1145–1155. This study explores the the intracellular signaling pathways involved in crystal-induced mitogen-activated protein kinase signal transduction and interleukin-8 transcriptional activation in human monocytic cells.
Gillespie E, Levine RJ, Malawista SE: Histamine release from rat peritoneal mast cells: inhibition by colchicines and potentiation by deuterium oxide. J Pharmacol Exp Ther 1968, 164:158–165.
Pouliot M, James MJ, McColl SR, et al.: Monosodium urate microcrystals induce cyclooxygenase-2 in human monocytes. Blood 1998, 91:1769–1776. This paper describes the effect of monosodium urate crystals on monocyte cyclooxygenase-2 and prostanoid production, which is inhibited by colchicine.
Fordham JN, Kirwan J, Cason J, Currey HLF: Prolonged reduction in polymorphonuclear adhesion following oral colchicine. Ann Rheum Dis 1981, 40:605–608.
Asako H, Kubes P, Baethge BA, et al.: Colchicine and methotrexate reduce leukocyte adherence and emigration in rat mesenteric venules. Inflammation 1992, 16:45–56.
Cronstein BN, Weissmann G: The adhesion molecules of inflammation. Arthritis Rheum 1993, 36:147–157.
Cronstein BN, Molad Y, Reibman J, et al.: Colchicine alters the quantitative and qualitative display of selectins on endothelial cells and neutrophils. J Clin Invest 1995, 96:994–1002.
Paya M, Terencio MC, Ferrandiz ML, Alcaraz MJ: Involvement of secretory phospholipase A2 activity in the zymosan air pouch model of inflammation. Br J Pharmacol 1996, 117:1773–1779.
Zurier RB, Hoffstein S, Weissmann G: Mechanisms of lysosomal enzyme release from human leukocytes: I, effect of cyclic nucleotides and colchicine. J Cell Biol 1973, 58:27–41.
Wright DG, Malawista SE: Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylates. Arthritis Rheum 1973, 16:749–758.
Roberge CJ, Gaudry M, De Medicis R, et al.: Crystal-induced neutrophil activation: IV, specific inhibition of tyrosine phosphorylation by colchicine. J Clin Invest 1993, 92:1722–1729.
Roberge CJ, Gaudry M, Gilbert C, et al.: Paradoxical effects of colchicines on the activation of human neutrophils by chemotactic factors and inflammatory micricrystals. J Leukoc Biol 1996, 59:864–871.
Peters-Golden M, McNish RW, Davis JA, et al.: Colchicine inhibits arachidonate release and 5-lipoxygenase action in alveolar macrophages. Am J Physiol 1996, 271:L1004-L1013.
Mekori YA, Baram D, Goldberg A, Klajman A: Inhibition of delayed hypersensitivity reactions in mice by colchicine. Cell Immunol 1989, 120:330–340.
Gillespie E, Lichtenstein LM: Histamine release from human leukocytes: studies with deuterium oxide, colchicine and cytochalasine B. J Clin Invest 1972, 51:2941–2947.
Malaisse WJ, Malaisse-Lagae F, Van Obbergen E, et al.: Role of microtubules in the phasic pattern of insulin release. Ann NY Acad Sci 1975, 253:630–652.
Reaven EP, Reaven GM: A quantitative ultrastructural study of microtubule content and secretory granule accumulation in parathyroid glands of phosphate and colchicine treated rats. J Clin Invest 1975, 56:49–55.
Bonfoco E, Ceccatelli S, Manzo L, Nicotera P: Colchicine induces apoptosis in cerebellar granule cells. Exp Cell Res 1995, 218:189–200.
Emmerson BT: The management of gout. N Engl J Med 1996, 334:445–451.
Ahern MJ, Reid C, Gordon TP, et al.: Does colchicine work? The results of the first controlled study in acute gout. Aust NZ J Med 1987, 17:301–304.
Wallace SL, Singer JZ: Review: systemic toxicity associated with the intravenous administration of colchicine-guidelines for use. J Rheumatol 1988, 15:495–499.
Roberts WN, Liang MH, Stern SH: Colchicine in acute gout: reassessment of risks and benefits. JAMA 1987, 257:1920–1922.
Paulus HE, Schlosstein LH, Godfrey RG, et al.: Prophylactic colchicine therapy of intercritical gout: a placebo-controlled study of probenecid-treated patients. Arthritis Rheum 1974, 17:609–614.
Ben-Chetrit E, Levy M: Colchicine: 1998 update. Semin Arthritis Rheum 1998, 28:48–59. An update on the use of colchicine in familial Mediterranean fever, with detailed description of the drug’s side effects.
Baud FJ, Sabouraud A, Vicaut E, et al.: Brief report: treatment of severe colchicine overdose with colchicine-specific Fab fragment. N Engl J Med 1995, 332:642–645.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Molad, Y. Update on colchicine and its mechanism of action. Curr Rheumatol Rep 4, 252–256 (2002). https://doi.org/10.1007/s11926-002-0073-2
Issue Date:
DOI: https://doi.org/10.1007/s11926-002-0073-2